Semaglutide 7.2mg Higher Dose: What More Wegovy Means

Why a Higher Dose?

When Wegovy launched with a maximum dose of 2.4mg weekly, it represented a major advance in obesity treatment. But clinical experience has shown that many patients — particularly those with higher BMIs — could benefit from additional appetite suppression and metabolic effect. Some patients plateau at 2.4mg without reaching their weight loss goals.

The 7.2mg dose represents a tripling of the current maximum, achieved through an extended titration schedule with intermediate steps. Novo Nordisk designed the STEP UP trial program to determine whether this higher dose could safely produce additional weight loss while maintaining an acceptable side effect profile.

This development also represents Novo Nordisk's competitive response to tirzepatide (Zepbound/Mounjaro), which at its highest doses produces approximately 20-22% weight loss — roughly 5 percentage points more than Wegovy 2.4mg. By offering a higher semaglutide dose, Novo Nordisk aims to close this efficacy gap. Learn about current GLP-1 treatment options.

STEP UP Trial Results

The Extended Titration Schedule

Reaching 7.2mg requires a slower, more gradual titration than the current Wegovy schedule. This extended escalation is critical for tolerability:

The full titration to 7.2mg takes approximately 28 weeks, compared to 16 weeks for the current 2.4mg target. This longer ramp-up period means patients need patience during the escalation phase but typically experience less severe GI side effects at each step because the dose increments are proportionally smaller.

Who Could Benefit Most

The higher dose is not for everyone. Patients most likely to benefit include:

• Patients who plateau at 2.4mg: If you have been on the current maximum dose for 3+ months and weight loss has stalled despite good adherence and lifestyle efforts, a higher dose may restart progress.
• Patients with BMI above 40: Higher BMI patients often need greater pharmacological support. The additional weight loss from 7.2mg may be necessary to achieve health-meaningful outcomes.
• Patients who tolerate 2.4mg well: If you have minimal side effects at the current maximum dose, you are more likely to tolerate higher doses without significant issues.
• Patients who need to avoid surgery: For patients who would otherwise consider bariatric surgery, the 7.2mg dose may provide enough weight loss to achieve their goals without an operation.

Conversely, patients who struggle with GI side effects at 2.4mg are unlikely to tolerate 7.2mg. Patients who have achieved satisfactory weight loss at 2.4mg do not need to increase their dose. Learn more about how semaglutide works.

Side Effects at Higher Doses

The 7.2mg dose showed a predictably higher rate of GI side effects compared to 2.4mg:

• Nausea: More common during dose escalation, particularly at the 3.6mg and 5.0mg steps. Most was mild and resolved within 1-2 weeks at each dose level.
• Vomiting and diarrhea: Modestly increased compared to 2.4mg but generally manageable.
• Discontinuation due to side effects: Slightly higher than at 2.4mg, but the majority of patients who reached the 7.2mg dose tolerated it for the duration of the trial.
• Serious adverse events: No new safety signals emerged at the higher dose. The types of serious events were consistent with what has been observed with semaglutide 2.4mg.

Competitive Implications

The 7.2mg dose significantly changes the competitive dynamics in the weight loss medication market. At approximately 20-22% weight loss, semaglutide 7.2mg is now directly competitive with tirzepatide 15mg, eliminating what had been a meaningful efficacy gap. Combined with semaglutide's longer track record, established cardiovascular outcomes data (SELECT trial), and broader prescriber familiarity, the higher dose strengthens Novo Nordisk's competitive position.

For patients and payers, greater competition between equally effective products should ultimately drive better pricing and access.

Frequently Asked Questions